方法：回顾性分析了我院2008-05/2010-05收治的22例23眼新生血管性青光眼患者的临床资料。所有患者均接受玻璃体腔注射Bevacizumab治疗，3～5d后根据患者接受治疗的方法分为青光眼引流阀植入术组(A组，13眼)和小梁切除术组(B组，10眼)。术后随访12～26mo，分别对两组术后视力、眼压、虹膜新生血管和并发症发生率进行比较。

结果：所有患者经Bevacizumab治疗3～5d后虹膜新生血管消退或大部分消退，有效率为100%。A组患者治疗后视力改善率明显高于B组(P<0.05)，其中B组1例患者视力下降。A组和B组患者术后眼压较术前明显下降(P<0.05)，而远期随访A组术后平均眼压明显低于B组(P<0.05)。A组和B组术后并发症发生率比较无统计学意义(P>0.05)。

结论：玻璃体腔注射Bevacizumab联合引流阀植入术治疗新生血管性青光眼可改善患者视力，较小梁切除术更有效控制眼压，且并发症少，值得临床推广使用。

METHODS: Totally 22 patients(23 eyes)with neovascular glaucoma from May 2008 to May 2010 were analyzed retrospectively. All patients were treated with intravitreous injection of Bevacizumab. After 3-5d, 13 eyes were treated with glaucoma valve implantation(group A)and 10 eyes were treated with trabeculectomy(group B). The period of follow-up was 12-26mo. The postoperative visual acuity, intraocular pressure, iris neovascularization and complication rate were compared between the two groups.

RESULTS: Iris neovascularization in group A and group B decreased or completely disappeared after 3-5d intravitreous injection of Bevacizumab. The success rate was 100%. The ratio of improved visual acuity in group A was significantly higher than that of group B(P<0.05), what's more, visual acuity of one patient decreased in group B. Compared with that before operation, intraocular pressure in group A and group B significantly decreased(P<0.05), but the average of intraocular pressure in group A was lower than that of group B during the long term follow-up(P<0.05). Complication rate had no statistical difference between group A and group B(P>0.05).

CONCLUSION: Intravitreous injection of Bevacizumab combined with glaucoma valve implantation is worth clinical application for improving visual acuity. Compared with trabeculectomy, it can control intraocular pressure better and reduce complication in patients with neovascular glaucoma.